Restricting efferocytosis pathway to CD91 via phosphatidylserine-targeting chimeric protein augments antitumor immune

Yu Mizote1, Hiroki Nishita2, Kazuki Hashiba3

  • 1Department of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan; Department of Cancer Immunotherapy, Research Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan.

Related Concept Videos